ResearchIn-Press PreviewGastroenterologyImmunology
Open Access | 10.1172/jci.insight.179315
1Department of Surgery, Section of Thoracic Surgery, University of Michigan Medical School, Ann Arbor, United States of America
2Department of Radiation Oncology, University of Michigan Medical School, Ann Arbor, United States of America
3Department of Pathology, University of Michigan Medical School, Ann Arbor, United States of America
Find articles by McEwen, D. in: JCI | PubMed | Google Scholar
1Department of Surgery, Section of Thoracic Surgery, University of Michigan Medical School, Ann Arbor, United States of America
2Department of Radiation Oncology, University of Michigan Medical School, Ann Arbor, United States of America
3Department of Pathology, University of Michigan Medical School, Ann Arbor, United States of America
Find articles by Ray, P. in: JCI | PubMed | Google Scholar
1Department of Surgery, Section of Thoracic Surgery, University of Michigan Medical School, Ann Arbor, United States of America
2Department of Radiation Oncology, University of Michigan Medical School, Ann Arbor, United States of America
3Department of Pathology, University of Michigan Medical School, Ann Arbor, United States of America
Find articles by
Nancarrow, D.
in:
JCI
|
PubMed
|
Google Scholar
|
1Department of Surgery, Section of Thoracic Surgery, University of Michigan Medical School, Ann Arbor, United States of America
2Department of Radiation Oncology, University of Michigan Medical School, Ann Arbor, United States of America
3Department of Pathology, University of Michigan Medical School, Ann Arbor, United States of America
Find articles by Wang, Z. in: JCI | PubMed | Google Scholar
1Department of Surgery, Section of Thoracic Surgery, University of Michigan Medical School, Ann Arbor, United States of America
2Department of Radiation Oncology, University of Michigan Medical School, Ann Arbor, United States of America
3Department of Pathology, University of Michigan Medical School, Ann Arbor, United States of America
Find articles by Kasturirangan, S. in: JCI | PubMed | Google Scholar
1Department of Surgery, Section of Thoracic Surgery, University of Michigan Medical School, Ann Arbor, United States of America
2Department of Radiation Oncology, University of Michigan Medical School, Ann Arbor, United States of America
3Department of Pathology, University of Michigan Medical School, Ann Arbor, United States of America
Find articles by Abdullah, S. in: JCI | PubMed | Google Scholar
1Department of Surgery, Section of Thoracic Surgery, University of Michigan Medical School, Ann Arbor, United States of America
2Department of Radiation Oncology, University of Michigan Medical School, Ann Arbor, United States of America
3Department of Pathology, University of Michigan Medical School, Ann Arbor, United States of America
Find articles by Balan, A. in: JCI | PubMed | Google Scholar
1Department of Surgery, Section of Thoracic Surgery, University of Michigan Medical School, Ann Arbor, United States of America
2Department of Radiation Oncology, University of Michigan Medical School, Ann Arbor, United States of America
3Department of Pathology, University of Michigan Medical School, Ann Arbor, United States of America
Find articles by Hoskeri, R. in: JCI | PubMed | Google Scholar
1Department of Surgery, Section of Thoracic Surgery, University of Michigan Medical School, Ann Arbor, United States of America
2Department of Radiation Oncology, University of Michigan Medical School, Ann Arbor, United States of America
3Department of Pathology, University of Michigan Medical School, Ann Arbor, United States of America
Find articles by Thomas, D. in: JCI | PubMed | Google Scholar
1Department of Surgery, Section of Thoracic Surgery, University of Michigan Medical School, Ann Arbor, United States of America
2Department of Radiation Oncology, University of Michigan Medical School, Ann Arbor, United States of America
3Department of Pathology, University of Michigan Medical School, Ann Arbor, United States of America
Find articles by
Lawrence, T.
in:
JCI
|
PubMed
|
Google Scholar
|
1Department of Surgery, Section of Thoracic Surgery, University of Michigan Medical School, Ann Arbor, United States of America
2Department of Radiation Oncology, University of Michigan Medical School, Ann Arbor, United States of America
3Department of Pathology, University of Michigan Medical School, Ann Arbor, United States of America
Find articles by
Beer, D.
in:
JCI
|
PubMed
|
Google Scholar
|
1Department of Surgery, Section of Thoracic Surgery, University of Michigan Medical School, Ann Arbor, United States of America
2Department of Radiation Oncology, University of Michigan Medical School, Ann Arbor, United States of America
3Department of Pathology, University of Michigan Medical School, Ann Arbor, United States of America
Find articles by Lagisetty, K. in: JCI | PubMed | Google Scholar
1Department of Surgery, Section of Thoracic Surgery, University of Michigan Medical School, Ann Arbor, United States of America
2Department of Radiation Oncology, University of Michigan Medical School, Ann Arbor, United States of America
3Department of Pathology, University of Michigan Medical School, Ann Arbor, United States of America
Find articles by
Ray, D.
in:
JCI
|
PubMed
|
Google Scholar
|
Published May 23, 2024 - More info
Immunosuppression is a common feature of esophageal adenocarcinoma (EAC) and has been linked to poor overall survival (OS). We hypothesized that upstream factors might negatively influence CD3 levels and T-cell activity, thus promoting immunosuppression and worse survival. We used clinical data and patient samples of those who progressed from Barrett’s (BE) to dysplasia to EAC, investigated gene (RNAseq), protein (tissue microarray) expression and performed cell biology studies to delineate a pathway impacting CD3 protein stability that might influence EAC outcome. We show that the loss of both CD3-ε expression and CD3+ T-cell number are correlated with worse OS in EAC. The GRAIL (gene related to anergy in lymphocytes) isoform 1 (GRAIL1), which is the prominent isoform in EACs, degrades (ε, γ, δ) CD3s and inactivates T-cells. In contrast, isoform 2 (GRAIL2), which is reduced in EACs, stabilizes CD3s. Further, GRAIL1 mediated CD3 degradation is facilitated by interferon stimulated gene 15 (ISG15), a ubiquitin-like protein. Consequently, either the overexpression of a ligase-dead GRAIL1, ISG15 knockdown, or the overexpression of a conjugation-defective ISG15-LRAA mutant can increase CD3 levels. Together, we identified that an ISG15→GRAIL1→mutant p53 amplification loop negatively influencing CD3 levels and T-cell activity, thus promoting immunosuppression in EAC.